CAS: 40925-70-0; 2-Amino-5-Methoxyphenol

上下游产品

CAS号704-14-3 5-甲氧基-2-硝基苯酚 | CAS号88581-05-9 Phenol, 4-chlor... | CAS号150-19-6 3-甲氧基苯酚 | CAS号13895-38-0 4-亚硝基间苯二酚1-单甲醚 | CAS号91-66-7 N,N-二乙基苯胺 | CAS号56661-22-4 2-hydroxy-4-met... | CAS号89232-58-6 O-(3-methoxyphe... | CAS号2051-85-6 苏丹橙G | CAS号7647-01-0 盐酸 | CAS号58243-21-3 5-methoxy-1,2-n... | CAS号477601-28-8 6-甲氧基-8-喹啉醇 | CAS号6529-94-8 7-甲氧基-2H-苯并[b][... | CAS号532-91-2 薏苡素 | CAS号101908-49-0 N-(2-羟基-4-甲氧基苯基)丙酰胺 | CAS号140413-17-8 9-methoxy-6-met... | CAS号17359-53-4 2H-1,4-Benzoxaz... | CAS号81066-48-0 7-methoxy-4H-1,... | CAS号88972-91-2 2,6-ditert-buty... | CAS号58469-06-0 N-(2-羟基-4-甲氧基苯基)乙酰胺

📜5-氟-2-硝基苯酚置于palladium 10% On Activated Carbon,氢气体系中,用 甲醇,乙醇 作为反应溶剂,20.0~60.0 °C,413.7 Kpa 条件下,反应 56.0H,反应生成 2-氨基-5-甲氧基苯酚
参考文献:Hmox1 Inducers
标题:Hmox1 Inducers
摘要:本发明涉及结构(i)的化合物作为血红素氧合酶1(hmox 1)诱导剂.本发明还涉及一种控制哺乳动物体内血红素氧合酶1的活性或数量,或活性和数量的方法.这里提供了变量的定义.

专利信息

专利号:US-2004209877-A1
优先权日:2000-04-13
标 题 :Methods for augmenting immune defenses contemplating the administration of phenolic and indoleamine-like compounds for use in animals ans humans
发明人：SHELBY NANCY J; ROSENFELD MARK J
摘要:Phenolic compounds with a phenolic molecule to which are covalently linked an oxygen-containing group, a nitrogen or another oxygen containing group, and a C 1 -C 4 alkoxy group, obtainable from monocotyledonous plants, or by chemical synthesis, have been found to preserve and/or augment innate immune defenses in humans and animals. Additional chemical compounds of the present invention may include benzoxazinoids-cyclic hydroxyamic acids, lactams, and corresponding glucosides, which may serve as precursors to phenolic compounds. The phenolic compounds and precursors of phenolic compounds of the present invention, at concentrations suitable for human and animal therapeutic use, may be obtained from monocotyledonous plants such as corn in their early growth states which are timely harvested for optimum yield.

专利号:WO-2010048514-A1
优先权日:2008-10-23
标题:Synthesis of 2-aminobenzoxazole compounds

专利号:US-7794761-B2
优先权日:2000-04-13
标 题:Methods for inducing anti-anxiety and calming effects in animals and humans
发明人：SHELBY NANCY J; GODFREY MITCHELL T; ROSENFELD MARK J
权利人:SEROCTIN RES & TECHNOLOGY INC
摘要:Phenolic compounds with a phenolic molecule to which are covalently linked an oxygen-containing group, a nitrogen or another oxygen containing group, and a C 1 -C 4 alkoxy group, or their precursor compounds, obtainable from monocotyledonous plants, or by chemical synthesis, have been found to calm and/or reduce anxiety and related behaviors and states in humans and animals. Additional chemical compounds of the present invention may include benzoxazinoids-cyclic hydroxyamic acids, lactams, and corresponding glucosides, which may serve as precursors to phenolic compounds. The phenolic compounds and precursors of phenolic compounds of the present invention, at concentrations suitable for human and animal therapeutic use, may be obtained from monocotyledonous plants such as corn in their early growth states which are timely harvested for optimum yield.

专利号:US-5760054-A
优先权日:1994-04-14
标题:Alpha IC adrenergic receptor antagonists
发明人：HUFF JOEL R; LEE HEE-YOON; NERENBERG JENNIE B; THOMPSON WAYNE J; BELL IAN M
权利人:MERCK & CO INC
摘要:PCT No. PCT/US95/04590 Sec. 371 Date Oct. 1, 1996 Sec. 102(e) Date Oct. 1, 1996 PCT Filed Apr. 13, 1995 PCT Pub. No. WO95/28397 PCT Pub. Date Oct. 26, 1995This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1C adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hypertrophy. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha1C receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.